{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:30:06Z","timestamp":1786620606738,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-024-03424-3","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T14:37:16Z","timestamp":1734791836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Shengfa","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihe","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"issue":"2","key":"3424_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/bcr2574","volume":"12","author":"RD Chac\u00f3n","year":"2010","unstructured":"Chac\u00f3n RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res. 2010;12(2):S3. https:\/\/doi.org\/10.1186\/bcr2574.","journal-title":"Breast Cancer Res"},{"issue":"11","key":"3424_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66. Epub 2016\/10\/19.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10087","key":"3424_CR3","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/s0140-6736(16)32454-0","volume":"389","author":"C Denkert","year":"2017","unstructured":"Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430\u201342. https:\/\/doi.org\/10.1016\/s0140-6736(16)32454-0. Epub 2016\/12\/13.","journal-title":"Lancet"},{"issue":"9814","key":"3424_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"G Collaborative","year":"2012","unstructured":"Early Breast Cancer Trialists\u2019, Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (London England). 2012;379(9814):432\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(11)61625-5.","journal-title":"Lancet (London England)"},{"issue":"8","key":"3424_CR5","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The Triple negative Paradox: primary tumor chemosensitivity of breast Cancer subtypes. Clin Cancer Res. 2007;13(8):2329. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1109.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3424_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-Approved Immune Checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738. https:\/\/doi.org\/10.3390\/cancers12030738.","journal-title":"Cancers (Basel)"},{"issue":"27","key":"3424_CR7","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/jco.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959\u201366. https:\/\/doi.org\/10.1200\/jco.2013.55.0491.","journal-title":"J Clin Oncol"},{"issue":"6127","key":"3424_CR8","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer Genome Landscapes Sci. 2013;339(6127):1546. https:\/\/doi.org\/10.1126\/science.1235122.","journal-title":"Cancer Genome Landscapes Sci"},{"issue":"4","key":"3424_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.Cir-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361\u201370. https:\/\/doi.org\/10.1158\/2326-6066.Cir-13-0127. Epub 2014\/04\/26.","journal-title":"Cancer Immunol Res"},{"issue":"21","key":"3424_CR10","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/jco.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with Advanced Triple-negative breast Cancer: phase ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460\u20137. https:\/\/doi.org\/10.1200\/jco.2015.64.8931.","journal-title":"J Clin Oncol"},{"issue":"13 Supplement","key":"3424_CR11","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1158\/1538-7445.AM2017-2986","volume":"77","author":"P Schmid","year":"2017","unstructured":"Schmid P, Cruz C, Braiteh FS, Eder JP, Tolaney S, Kuter I, et al. Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and biomarker analyses. Cancer Res. 2017;77(13 Supplement):2986. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-2986.","journal-title":"Cancer Res"},{"issue":"22","key":"3424_CR12","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-negative breast Cancer. N Engl J Med. 2018;379(22):2108\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1809615.","journal-title":"N Engl J Med"},{"key":"3424_CR13","doi-asserted-by":"publisher","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019(a);30(3):405\u2009\u2013\u200911. https:\/\/doi.org\/10.1093\/annonc\/mdy518.","DOI":"10.1093\/annonc\/mdy518"},{"key":"3424_CR14","doi-asserted-by":"publisher","unstructured":"Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study. Ann Oncol 2019(b);30(3):397\u2013404. https:\/\/doi.org\/10.1093\/annonc\/mdy517.","DOI":"10.1093\/annonc\/mdy517"},{"issue":"3","key":"3424_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00262-010-0930-1","volume":"60","author":"R Ramakrishnan","year":"2011","unstructured":"Ramakrishnan R, Gabrilovich DI. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother. 2011;60(3):419\u201323. https:\/\/doi.org\/10.1007\/s00262-010-0930-1. Epub 2010\/10\/27.","journal-title":"Cancer Immunol Immunother"},{"key":"3424_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2021.03.049","volume":"151","author":"K Mori","year":"2021","unstructured":"Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, et al. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: a systematic review and meta-analysis. Eur J Cancer. 2021;151:35\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.049.","journal-title":"Eur J Cancer"},{"key":"3424_CR17","doi-asserted-by":"publisher","first-page":"175883592097713","DOI":"10.1177\/1758835920977137","volume":"12","author":"T Landre","year":"2020","unstructured":"Landre T, Chouahnia K, Des Guetz G, Duchemann B, Assi\u00e9 J-B, Choua\u00efd C. First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920977137. https:\/\/doi.org\/10.1177\/1758835920977137.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"3424_CR18","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1002\/jcp.29371","volume":"235","author":"C Wang","year":"2020","unstructured":"Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Wang T, et al. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cell Physiol. 2020;235(5):4913\u201327. https:\/\/doi.org\/10.1002\/jcp.29371.","journal-title":"J Cell Physiol"},{"issue":"8","key":"3424_CR19","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279\u201388. https:\/\/doi.org\/10.1093\/annonc\/mdz158.","journal-title":"Ann Oncol"},{"issue":"4 Supplement","key":"3424_CR20","doi-asserted-by":"publisher","first-page":"GS3","DOI":"10.1158\/1538-7445.SABCS19-GS3-04","volume":"80","author":"L Gianni","year":"2020","unstructured":"Gianni L, Huang C-S, Egle D, Bermejo B, Zamagni C, Thill M, et al. Abstract GS3-04: pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res. 2020;80(4 Supplement):GS3\u201304. https:\/\/doi.org\/10.1158\/1538-7445.SABCS19-GS3-04.","journal-title":"Cancer Res"},{"issue":"10257","key":"3424_CR21","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/s0140-6736(20)31953-x","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090\u2013100. https:\/\/doi.org\/10.1016\/s0140-6736(20)31953-x.","journal-title":"Lancet"},{"issue":"5","key":"3424_CR22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete response in women with early-stage breast Cancer: an analysis of the Ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6650.","journal-title":"JAMA Oncol"},{"issue":"9","key":"3424_CR23","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast Cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"issue":"1","key":"3424_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44\u201359. https:\/\/doi.org\/10.1016\/s1470-2045(19)30689-8.","journal-title":"Lancet Oncol"},{"issue":"10265","key":"3424_CR25","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9.","journal-title":"Lancet"},{"key":"3424_CR26","doi-asserted-by":"publisher","unstructured":"Miles DW, Gligorov J, Andr\u00e9 F, Cameron D, Schneeweiss A, Barrios CH, et al. LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) \u00b1 atezolizumab (atezo) for unresectable locally advanced\/metastatic triple-negative breast cancer (mTNBC). Annals of Oncology.2020;31:S1147-S8. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2243.","DOI":"10.1016\/j.annonc.2020.08.2243"},{"issue":"12","key":"3424_CR27","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1038\/s41591-022-02126-1","volume":"28","author":"AH R\u00f8ssevold","year":"2022","unstructured":"R\u00f8ssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, et al. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nat Med. 2022;28(12):2573\u201383.","journal-title":"Nat Med"},{"issue":"8","key":"3424_CR28","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1158\/2767-9764.CRC-21-0143","volume":"2022","author":"MA Florez","year":"2022","unstructured":"Florez MA, Kemnade JO, Chen N, Du W, Sabichi AL, Wang DY, et al. Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access. Cancer Res Commun. 2022;2022(8):806\u201313.","journal-title":"Cancer Res Commun"},{"key":"3424_CR29","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3389\/fonc.2020.01671","volume":"10","author":"X Yan","year":"2020","unstructured":"Yan X, Tian X, Wu Z, Han W. Impact of age on the efficacy of Immune Checkpoint inhibitor-based combination therapy for non-small-cell lung Cancer: a systematic review and Meta-analysis. Front Oncol. 2020;10:1671.","journal-title":"Front Oncol"},{"issue":"3","key":"3424_CR30","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583. https:\/\/doi.org\/10.1371\/journal.pmed.1003583. Epub 2021\/03\/30.","journal-title":"PLoS Med"},{"key":"3424_CR31","unstructured":"Review Manager Web (RevMan Web). The Cochrane Collaboration. (2019), Available at revman.cochrane.org."},{"issue":"3","key":"3424_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"issue":"7414","key":"3424_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Res ed). 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"1","key":"3424_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","volume":"5","author":"LA Emens","year":"2019","unstructured":"Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term clinical outcomes and biomarker analyses of Atezolizumab Therapy for patients with metastatic triple-negative breast Cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74\u201382.","journal-title":"JAMA Oncol"},{"issue":"4","key":"3424_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Mu\u00f1oz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499\u2013511. https:\/\/doi.org\/10.1016\/s1470-2045(20)30754-3. Epub 2021\/03\/08.","journal-title":"Lancet Oncol"},{"key":"3424_CR36","doi-asserted-by":"publisher","first-page":"1206689","DOI":"10.3389\/fimmu.2023.1206689","volume":"14","author":"Y Yu","year":"2023","unstructured":"Yu Y, Jin X, Zhu X, Xu Y, Si W, Zhao J. PD-1\/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1206689.","journal-title":"Front Immunol"},{"issue":"1","key":"3424_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12935-023-02941-7","volume":"23","author":"I Elmakaty","year":"2023","unstructured":"Elmakaty I, Abdo R, Elsabagh A, Elsayed A, Malki MI. Comparative efficacy and safety of PD-1\/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials. Cancer Cell Int. 2023;23(1):90.","journal-title":"Cancer Cell Int"},{"issue":"13","key":"3424_CR38","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2217\/imt-2023-0023","volume":"15","author":"W Zhang","year":"2023","unstructured":"Zhang W, He Y, Tang Y, Dai W, Si Y, Mao F, et al. A meta-analysis of application of PD-1\/PD-L1 inhibitor-based immunotherapy in unresectable locally advanced triple-negative breast cancer. Immunotherapy. 2023;15(13):1073\u201388.","journal-title":"Immunotherapy"},{"key":"3424_CR39","doi-asserted-by":"publisher","unstructured":"Sternschuss M, Yerushalmi R, Saleh RR, Amir E, Goldvaser H. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2021. Epub 2021\/03\/22. https:\/\/doi.org\/10.1007\/s00432-021-03591-w. PubMed PMID: 33745080.","DOI":"10.1007\/s00432-021-03591-w"},{"key":"3424_CR40","doi-asserted-by":"publisher","first-page":"175883592094092","DOI":"10.1177\/1758835920940928","volume":"12","author":"Y Zou","year":"2020","unstructured":"Zou Y, Zou X, Zheng S, Tang H, Zhang L, Liu P, et al. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920940928. PubMed PMID: 32874208; PubMed Central PMCID: PMCPMC7436841.","journal-title":"Ther Adv Med Oncol"},{"key":"3424_CR41","doi-asserted-by":"publisher","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (London, England). 2017;389(10066):255\u2009\u2013\u200965. Epub 2016\/12\/17. https:\/\/doi.org\/10.1016\/s0140-6736(16)32517-x. PubMed PMID: 27979383.","DOI":"10.1016\/s0140-6736(16)32517-x"},{"issue":"1","key":"3424_CR42","doi-asserted-by":"publisher","first-page":"1781333","DOI":"10.1080\/2162402X.2020.1781333","volume":"9","author":"L Peng","year":"2020","unstructured":"Peng L, Qin B-D, Xiao K, Xu S, Yang J-S, Zang Y-S, et al. A meta-analysis comparing responses of Asian versus non-asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. OncoImmunology. 2020;9(1):1781333. https:\/\/doi.org\/10.1080\/2162402X.2020.1781333.","journal-title":"OncoImmunology"},{"issue":"2","key":"3424_CR43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10549-017-4529-5","volume":"167","author":"JA Malmgren","year":"2018","unstructured":"Malmgren JA, Mayer M, Atwood MK, Kaplan HG. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990\u20132010. Breast Cancer Res Treat. 2018;167(2):579\u201390.","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"3424_CR44","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jco.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714\u201368. https:\/\/doi.org\/10.1200\/jco.2017.77.6385. Epub 2018\/02\/15.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3424_CR45","doi-asserted-by":"publisher","first-page":"e001112","DOI":"10.1136\/esmoopen-2020-001112","volume":"5","author":"MA Franzoi","year":"2020","unstructured":"Franzoi MA, de Azambuja E. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? ESMO Open. 2020;5(6):e001112\u2013e. https:\/\/doi.org\/10.1136\/esmoopen-2020-001112.","journal-title":"ESMO Open"},{"issue":"4","key":"3424_CR46","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/onco.13680","volume":"26","author":"T Janowitz","year":"2021","unstructured":"Janowitz T, Kleeman S, Vonderheide RH. Reconsidering dexamethasone for Antiemesis when combining chemotherapy and immunotherapy. Oncologist. 2021;26(4):269\u201373. https:\/\/doi.org\/10.1002\/onco.13680.","journal-title":"Oncologist"},{"issue":"7738","key":"3424_CR47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase ib glioblastoma trial. Nature. 2019;565(7738):234\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0792-9.","journal-title":"Nature"},{"issue":"4","key":"3424_CR48","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847\u201356. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983.","journal-title":"Mol Cancer Ther"},{"issue":"7suppl","key":"3424_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.35.7_suppl.7","volume":"35","author":"M Scott","year":"2017","unstructured":"Scott M, Ratcliffe MJ, Sharpe A, Barker C, Scorer P, Rebelatto M, et al. Concordance of tumor and immune cell staining with Ventana SP142, Ventana SP263, Dako 28\u2009\u2013\u20098 and Dako 22C3 PD-L1 tests in NSCLC patient samples. J Clin Oncol. 2017;35(7suppl):7.","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03424-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03424-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03424-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T15:01:55Z","timestamp":1734793315000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03424-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3424"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03424-3","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"346"}}